Sarepta Therapeutics, Inc. (25)

Browse by Contract Category

Contracts

Underwriting Agreement, October 13, 2021 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse... (Filed With SEC on October 15, 2021)
Amendment no. 4 dated June 23, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21, 2019 (Filed With SEC on August 4, 2021)
Offer Letter dated March 17, 2017 by and between Sarepta Therapeutics, Inc. and Joseph Bratica (Filed With SEC on March 1, 2021)
Separation and Consulting Agreement and General Release between David T. Howton Jr. and Sarepta Therapeutics, Inc (Filed With SEC on March 1, 2021)
Amendment No. 1 to License Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. on the one hand and BioMarin Leiden Holding BV, BioMarin Nederlands... (Filed With SEC on August 7, 2019)
Amendment no. 3 dated February 4, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on August 4, 2021)
Amendment no. 2 dated October 28, 2020 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on August 4, 2021)
Amendment no. 1 dated October 23, 2020 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd dated December 21,... (Filed With SEC on August 4, 2021)
Offer Letter dated by December 18, 2014 and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)
Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)
Offer Letter dated April 19, 2018 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)
Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)
First Amendment dated September 24, 2020 to Loan Agreement among Sarepta Therapeutics, Inc., BioPharma Credit PLC and BioPharma Credit Investments V (Master) LP dated December 13,... (Filed With SEC on November 5, 2020)
Separation Agreement and General Release between Sandesh Mahatme and Sarepta Therapeutics, Inc (Filed With SEC on August 5, 2020)
Amendment No. 1 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 8, 2020)
Description of Registered Securities (Filed With SEC on February 26, 2020)
Amendment No. 2 to the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on February 21, 2020)
Amendment No. 1 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employment Stock Purchase Plan (as Amended and Restated on June 27, 2016) (Filed With SEC on August 7, 2019)
Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on August 7, 2019)
Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 7, 2019)
Form of Change in Control and Severance Agreement entered into between Sarepta Therapeutics, Inc. and each of Sandesh Mahatme, David Tyronne Howton, Jr. and Alexander Bo Cumbo (Filed With SEC on May 8, 2019)
Form of Severance Letter Agreement entered into between Sarepta Therapeutics, Inc. and each of Sandesh Mahatme, David Tyronne Howton, Jr. and Alexander Bo Cumbo (Filed With SEC on May 8, 2019)
Letter Agreement between Sarepta Therapeutics, Inc. and Myonexus Therapeutics, Inc. dated February 26, 2019 (Filed With SEC on May 8, 2019)
Underwriting Agreement, March 5, 2019 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named... (Filed With SEC on March 7, 2019)
Amendment to Restricted Stock Award Agreement between Douglas S. Ingram and Sarepta Therapeutics, Inc. dated December 17, 2018 (Filed With SEC on February 28, 2019)